There is a wide spectrum of non-surgical treatments, starting with non-pharmacological options such as patient education and awareness, physical exercise and rehabilitation aids; pharmacological approaches that vary from prescription of acetaminophen, non-selective NSAIDs, selective COX-2 inhibitors agents and even opioid prescription. Other potential non-surgical therapeutic methods are chondroitin sulfate, glucosamine and other compounds in tablets or capsules, and intraarticular injections of visco-supplements, corticosteroids or blood-derived products.

Each injection has been shown to lower the pain in patients in some form, though hyaluronic acid treatments seem to be the safest and last the longest.

Carthyal® is is a line of products for OA. It includes:

• Carthyal^® Daily Care (serve the objective of delaying the natural progression of the OA. It does not serve as a definitive treatment but rather as a way to decelerate the development of the OA for patients with light to moderate symptoms. Carthyal^® Daily Care can be used in concomitance but does not replace other treatments, such as the injectables. The product unique composition is a mix of actives: 600 mg of glucosamine sulfate + 600 mg of chondroitin sulfate + 350 mg of MSM (Methylsulfonylmethane) + 100 mg Boswellia + 80 mg vitamin C, in 2 capsules/day).
• Carthyal^® Injectables with hyaluronic acid (HA) replace the synovial fluid in the joint and it is indicated in the prevention and treatments of trauma-caused and degenerative diseases in synovial joints.

The intra-articular administration of Carthyal^® allows:

• Immediate action by REDUCING the pain and inflammation

• Highly effective RESTORATION of the viscoelastic properties of the joints’ synovial fluid

• IMPROVEMENT of the articular mobility, with functional recovery of the joint

• PREVENTION the natural degradation of the joints

• SAFE, WIDELY documented treatment with less side effect

CARTHYAL^® Injetables is available in 3 different concentrations, different molecular weights and treatment options:

Carthyal^® ONE 2,5% (75mg/3ml):

• Cross-linked intercalated with linear hyaluronic acid, with a combined molecular weight of 3.000.000 Da (crossed linked HA fraction) + 500.000 Da (linear HA faction)
• Treatement with 1 injection

Carthyal^® PLUS 1,6% + 5% MSM (32mg/2ml HA + 100mg/2ml Methylsulfonylmethane):

• Sodium Hyaluronate with a molecular weight of 1.800.000 Da
• Treatement with an average of 3 injections

Carthyal^® 2% (40mg/2ml):

• Sodium Hyaluronate with a molecular weight between 800.000 and 1.200.000 Da
• Treatement with an average of 3 injections

Carthyal^® Injectables are European Medical Devices class III, produced in the E.U. under ISO 13485. Carthyal^® Daily Care is a European Food Supplement, produced in a cGMP facility.